Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.

Technology | Antiplatelet and Anticoagulation Therapies

May 17, 2019 — The U.S. Food and Drug Administration (FDA) this week approved Fragmin (dalteparin sodium) injection, for ...

Home May 17, 2019
Home
Technology | Antiplatelet and Anticoagulation Therapies

April 30, 2019 — PhaseBio Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted ...

Home April 30, 2019
Home
News | Antiplatelet and Anticoagulation Therapies

April 24, 2019 — New research from the University of Illinois at Chicago shows that when pharmacies close, people stop ...

Home April 24, 2019
Home
News | Antiplatelet and Anticoagulation Therapies

April 18, 2019 — A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second ...

Home April 18, 2019
Home
News | Antiplatelet and Anticoagulation Therapies

April 16, 2019 — HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT ...

Home April 16, 2019
Home
News | Antiplatelet and Anticoagulation Therapies

April 15, 2019 — Despite national guidelines indicating statins can lower risk of heart attack and stroke, many patients ...

Home April 15, 2019
Home
News | Antiplatelet and Anticoagulation Therapies

March 25, 2019 — Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but ...

Home March 25, 2019
Home
News | Antiplatelet and Anticoagulation Therapies

March 19, 2019 — The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating ...

Home March 19, 2019
Home
ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics

March 18, 2019 — The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a ...

Home March 18, 2019
Home
News | Antiplatelet and Anticoagulation Therapies

February 19, 2019 — A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and ...

Home February 19, 2019
Home
Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.
Feature | Atrial Fibrillation
January 30, 2019 — Updated atrial fibrillation (AFib) treatment guidelines released this week now recommend new oral ...
Home January 30, 2019
Home
News | Antiplatelet and Anticoagulation Therapies

January 2, 2019 — The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval ...

Home January 02, 2019
Home
News | Antiplatelet and Anticoagulation Therapies

December 17, 2018 — Among otherwise healthy people, a daily dose of aspirin does not save lives and causes additional ...

Home December 17, 2018
Home
News | Cardio-oncology

December 7, 2018 — New data from the Phase 3 CASSINI study showed a 60 percent reduction of venous thromboembolism (VTE ...

Home December 07, 2018
Home
Subscribe Now